NMRD

Nemaura Medical Inc.
CAPPED RATING

Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

Nemaura Medical Inc. (NMRD) is rated C (2.2/5) on Deltasharpe Prism, scored against General sector peers. Its strongest pillar is Profitability (C+); its weakest is Revisions (D).

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
C+
Factor Score 2.5 / 5.0
Momentum
C-
Factor Score 2.0 / 5.0
Revisions
D
Factor Score 1.5 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 46.3%
Price Return 3M 0.0%
Price Return 12M -50.0%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales N/A
ROE N/M

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2022-03-31 C+ (2.5) C+ (2.5) C+ (2.5) C- (2.0) D (1.5) C (2.2)
2021-12-31 C+ (2.5) C+ (2.5) D+ (1.8) C- (2.0) D (1.5) C- (2.1)